Fibrocor Therapeutics has appointed Mark Steedman as its first president and chief executive officer. He will also serve as a member of the company’s board of directors.
Fibrocor is focused on developing disease modifying therapeutics in fibrosis. Using a first-in class tissue discovery platform, Fibrocor has partnered with Evotec and MI to develop treatments to novel molecular targets and pathways in fibrosis.
Mr. Steedman is the co-founder of Interface Biologics where he most recently served as vice president of Business Development. His responsibilities there included all start-up operations including financing, which led to a Series A round totaling $13 million.
“We are extremely pleased to be able to recruit an executive with such extensive knowledge and background in life sciences venture-building” said Rafi Hofstein, president and chief executive officer of MI.
